Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).

BMS-823778 (2), a 1,2,4-triazolopyridinyl-methanol derived analog, was identified as a potent and selective inhibitor of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) enzyme (IC50 = 2.3 nM) with >10,000-fold selectivity over 11β-HSD-2. Compound 2 exhibits robust acute pharmacodynamic effects in cynomolgus monkeys (ED50 = 0.6 mg/kg) and in diet-induced obese (DIO) mice (ED50 = 34 mg/kg). Compound 2 also showed excellent inhibition in an ex vivo adipose DIO mouse model (ED50 = 5.2 mg/kg). Oral bioavailability ranges from 44% to 100% in preclinical species. Its favorable development properties, pharmacokinetics, high adipose-to-plasma concentration ratio, and preclinical pharmacology profile have prompted the evaluation of 2 for the treatment of type 2 diabetes and metabolic syndrome in phase 2 clinical trials.

[1]  L. Iacono,et al.  Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects , 2018, Drug Metabolism and Disposition.

[2]  Suresh B. Singh,et al.  Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor. , 2017, Bioorganic & medicinal chemistry.

[3]  David K. Leahy,et al.  Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. , 2017, Journal of medicinal chemistry.

[4]  James S. Scott,et al.  Medicinal chemistry of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). , 2014, Journal of medicinal chemistry.

[5]  Zaki K Hassan-Smith,et al.  11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess , 2014, Proceedings of the National Academy of Sciences.

[6]  S. Sheriff,et al.  Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1). , 2014, ACS Medicinal Chemistry Letters.

[7]  Jeremy W Tomlinson,et al.  11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. , 2013, Endocrine reviews.

[8]  Wen-pin Yang,et al.  11b-Hydroxysteroid Dehydrogenase Type 1 Gene Knockout Attenuates Atherosclerosis and In Vivo Foam Cell Formation in Hyperlipidemic apoE Mice , 2013 .

[9]  K. Svenson,et al.  Discovery of HSD-621 as a Potential Agent for the Treatment of Type 2 Diabetes. , 2013, ACS medicinal chemistry letters.

[10]  U. Ozbek,et al.  The role of mediastinal adipose tissue 11β-hydroxysteroid d ehydrogenase type 1 and glucocorticoid expression in the development of coronary atherosclerosis in obese patients with ischemic heart disease , 2012, Cardiovascular Diabetology.

[11]  L. Hamann,et al.  Generation of 3,8-substituted 1,2,4-triazolopyridines as potent inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1). , 2011, Bioorganic & medicinal chemistry letters.

[12]  K. Browman,et al.  Acute Inhibition of 11β-Hydroxysteroid Dehydrogenase Type-1 Improves Memory in Rodent Models of Cognition , 2011, The Journal of Neuroscience.

[13]  N. Morton.  Obesity and corticosteroids: 11β-Hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease , 2010, Molecular and Cellular Endocrinology.

[14]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[15]  T. Kowalski,et al.  11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents , 2009, Expert opinion on therapeutic patents.

[16]  J. Born,et al.  Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. , 2006, European journal of endocrinology.

[17]  P. Stewart,et al.  Mechanisms of Disease: selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome , 2005, Nature Clinical Practice Endocrinology &Metabolism.